Disclosed is the use of ACE2, for the production of a pharmaceutical composition for the therapeutic treatment or prevention of an inflammation selected from rheumatitis, sepsis, arthritis, rheumatoid systemic lupus erythematosus, scleroderma, an antiglomerular basal membrane disease, autoimmune diseases of the nervous system, systemic lupus erythematosus, Addisons disease, an antiphospholipid syndrome, an IgA glomerulonephritis, a Goodpasture syndrome, a Lambert-Eaton myasthenic syndrome, idiopathic purpura, an autoimmune thyroiditis, a rheumatoid arthritis, an insulin-dependent diabetes mellitus, a pemphigus, an autoimmune hemolytic anemia, a dermatitis herpetiformis During, a membranous glomerulonephritis, a Graves disease, a sympathetic ophthalmia, autoimmune polyendocrinopathies, multiple sclerosis and/or Reiters disease.
